Minister Bains announces investment in antibody discovery technology to help treat COVID-19
“Our government is mobilizing its resources to confront COVID-19, supporting the researchers and businesses that are working hard to develop medical countermeasures to beat this pandemic. Today’s contribution will support AbCellera Biologics as they use their world-leading technology to rapidly identify antibodies that could be used to develop a treatment for COVID-19 while ensuring Canada’s long-term preparedness for future health challenges.”
– The Honourable Navdeep Bains, Minister of Innovation, Science and Industry
“Each and every one of us is affected, and our teams stand together, galvanized to fight this outbreak. We are proud to have the support of the Government of Canada to quickly find a solution to the COVID-19 pandemic.”
– Carl Hansen, PhD, CEO of AbCellera
AbCellera has partnered with global biopharmaceutical company Eli Lilly to rapidly manufacture and distribute a treatment.
On April 23, 2020, the Government of Canada announced more than $1 billion in support of the Plan to Mobilize Science to fight COVID-19 that includes vaccine development, the production of treatments, and tracking of the virus. This includes $600 million through the Strategic Innovation Fund to support COVID-19 vaccine and therapy clinical trials led by the private sector as well as Canadian biomanufacturing opportunities. The establishment of the COVID-19 Immunity Task Force was also announced. The Task Force will oversee the coordination of a series of country-wide blood test surveys that will tell us how widely the virus has spread in Canada and provide reliable estimates of potential immunity and vulnerabilities in Canadian populations.
On March 23, 2020, the Government of Canada presented the Plan to Mobilize Science, a $275 million plan that makes significant investments in Canadian researchers working on countermeasures to combat COVID-19, including potential vaccines and treatments, support for clinical trials, and upgrades to facilities to develop, test and scale up promising vaccine candidates. The Strategic Innovation Fund contribution to AbCellera is part of this plan.
This contribution is also part of a larger strategy the Government of Canada is implementing to protect Canadians against COVID-19. This strategy prioritizes the health and safety of Canadians, ensures the capacity of our health care system, and mitigates the economic impacts on Canadians and Canadian business.
The National Research Council of Canada Industrial Research Assistance Program is collaborating with Innovative Solutions Canada to launch challenges seeking near-to-market solutions from Canadian small and medium-sized businesses that need financial support to refine and sell their products or solution to meet a COVID-19–related need.
The National Research Council of Canada has established a COVID-19 Pandemic Response Challenge Program, composed of teams of government, academic and private sector partners, to address specific COVID-19 gaps and challenges identified by Canadian health experts. The Challenge Program is structured around four main research pillars: rapid detection and diagnosis, therapeutics and vaccine development, digital health, and enabling adaptive responses.
- Coronavirus disease (COVID-19)
- Helping Canadians with the economic impact of the COVID-19 pandemic
- Prime Minister outlines Canada’s COVID-19 response
- Prime Minister announces new actions under Canada’s COVID-19 response
- Prime Minister announces more support for workers and businesses through Canada’s COVID-19 Economic Response Plan
- Prime Minister announces Canada’s Plan to Mobilize Science to fight COVID-19
- Prime Minister announces Canada’s Plan to Mobilize Industry to fight COVID-19
Office of the Minister of Innovation, Science and Industry
Innovation, Science and Economic Development Canada
Stay safe and connected
Follow Innovation, Science and Economic Development Canada on Twitter: @ISED_CA
Report a problem or mistake on this page
- Date modified: